1005196-13-3Relevant articles and documents
Homoleptic thiazole-based IrIII phosphorescent complexes for achieving both high EL efficiencies and an optimized trade-off among the key parameters of solution-processed WOLEDs
Guo, Haoran,Zhao, Jiang,Tian, Zhuanzhuan,Wu, Yong,Liu, Boao,Dang, Feifan,Yang, Xiaolong,Zhou, Guijiang,Wu, Zhaoxin,Wong, Wai-Yeung
, p. 208 - 219 (2017)
Two homoleptic thiazole-based IrIII phosphorescent emitters, Ir-3Tz1F and Ir-3Tz2F, with fluorinated 2-phenylthiazole-type ligands were designed and prepared. Their thermal stability, and photophysical and electrochemical properties, as well as electroluminescent (EL) performances in both monochromic OLEDs and solution-processed WOLEDs were investigated. When doped in monochromic OLEDs made by vacuum deposition, Ir-3Tz1F gave the maximum EL efficiencies with ηL of 56.2 cd A-1, ηext of 15.8% and ηp of 50.2 lm W-1. Critically, solution-processed WOLEDs based on Ir-3Tz1F with three primary colors could achieve an excellent trade-off among the stable balanced white EL spectra, a high EL efficiency and a high color rendering index (CRI). The optimized solution-processed WOLED exhibited very attractive EL efficiencies of 33.4 cd A-1, 16.5% and 30.6 lm W-1, while maintaining both a high CRI of ca. 80 and very stable Commission Internationale de L'Eclairage (CIE) coordinates in a wide driving voltage range from 4 V to 11 V.
Tris(cyclometalated) iridium(III) phosphorescent complexes with 2-phenylthiazole-type ligands: Synthesis, photophysical, redox and electrophosphorescent behavior
Yao, Chunliang,Jiao, Bo,Yang, Xiaolong,Xu, Xianbin,Dang, Jingshuang,Zhou, Guijiang,Wu, Zhaoxin,Lv, Xingqiang,Zeng, Yi,Wong, Wai-Yeung
, p. 4754 - 4763 (2013)
Tris(cyclometalated) iridium(III) phosphorescent emitters with 2-phenylthiazole-type ligands have been designed and synthesized. Their photophysical properties, electrochemical behavior and electroluminescent (EL) performance can be influenced by introduc
GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES
-
Paragraph 000869, (2015/04/15)
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES
-
Page/Page column 72, (2014/08/06)
The present invention relates to novel Thiazolyl-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2R3, R4 and R5 are as defined herein. The present
